GLSI - הערכת שווי הפעילות בספרים greenwichlifesciences.com
The pricing power of Greenwich LifeSciences (GLSI) is based on exclusive patents, which, if successful, will allow the company to establish monopoly pricing. However, the price action shown on the page, currently fixed at 0.00, accounts for risks: dependence on a single drug and a potential capital shortfall. At the same time, the business relies on the development of the GP2 vaccine, whose final FLAMINGO-01 tests could provide a market breakthrough.
Greenwich LifeSciences, Inc. - פילוחים אנליטיים ומדדי מפתח (GLSI)
Book value capitalization reflects the objective value of net assets, stripped of market speculation. Analyzing the current level of book value capitalization allows for a comparison of real capital against share prices. This metric is calculated as the difference between all of the issuer's assets and liabilities. For Greenwich LifeSciences (GLSI), this metric captures the intrinsic value of its resources, providing the financial foundation necessary to complete Phase III trials of its unique cancer vaccine.